Why the study?
Do P2Y12 receptor antagonists inhibit TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes?
Population
12 patients with acute coronary syndromes (ACS)
Design
Preclinical
Authors
Loading...
Animal data extend P2Y12 inhibition of TRAP responses; leaves open translation to ACS patients.
Do P2Y12 receptor antagonists inhibit TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes?
P2Y12 antagonists clopidogrel and AR-C69931MX inhibit TRAP-induced platelet aggregation and procoagulant activity, providing mechanistic insight into their clinical benefits in ACS.
Behan et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: